ProQR Therapeutics N.V. Forecast, price target & analysts
ProQR Therapeutics N.V. Target price 2025 - Analyst rating & recommendation
ProQR Therapeutics N.V. Classifications & Recommendation:
ProQR Therapeutics N.V. Price Target
| Target Price | $9.18 |
| Price | $1.89 |
| Potential |
385.71%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target ProQR Therapeutics N.V. 2026 .
The average ProQR Therapeutics N.V. target price is $9.18.
This is
385.71%
register free of charge
$14.70
677.78%
register free of charge
$4.04
113.76%
register free of charge
|
|
| A rating was issued by 15 analysts: 14 Analysts recommend ProQR Therapeutics N.V. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ProQR Therapeutics N.V. stock has an average upside potential 2026 of
385.71%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 22.71 | 20.74 |
| 105.15% | 8.65% | |
| EBITDA Margin | -141.74% | -298.95% |
| 53.97% | 110.91% | |
| Net Margin | -142.01% | -236.91% |
| 51.88% | 66.83% |
10 Analysts have issued a sales forecast ProQR Therapeutics N.V. 2025 . The average ProQR Therapeutics N.V. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an ProQR Therapeutics N.V. EBITDA forecast 2025. The average ProQR Therapeutics N.V. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 ProQR Therapeutics N.V. Analysts have issued a net profit forecast 2025. The average ProQR Therapeutics N.V. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.37 | -0.46 |
| 7.50% | 24.32% | |
| P/E | negative | |
| EV/Sales | 3.11 |
10 Analysts have issued a ProQR Therapeutics N.V. forecast for earnings per share. The average ProQR Therapeutics N.V. EPS is
This results in the following potential growth metrics and future valuations:
ProQR Therapeutics N.V....
Current ProQR Therapeutics N.V. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | May 13 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Apr 29 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Jun 27 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Jun 27 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
May 13 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Apr 29 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 14 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
